abstract |
Peptide drugs that inhibit the interaction between CAL and CFTR, and other proteins in cystic fibrosis and other diseases are described. These peptides have been chemically optimized to impart one or more of solubility, stability, cell permeability, mucus penetration, intracellular targeting and sequestration, increased potency and non-immunogenicity. |